Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Comparison of the efficacy of a diabetes education programme for type 1 diabetes (PRIMAS) in a randomised controlled trial setting and the effectiveness in a routine care setting : Results of a comparative effectiveness study

Publication

Comparison of the efficacy of a diabetes education programme for type 1 diabetes (PRIMAS) in a randomised controlled trial setting and the effectiveness in a routine care setting : Results of a comparative effectiveness study

Ehrmann, Dominic; Bergis-Jurgan, Nikola; Haak, Thomas; u. a. (2017): Comparison of the efficacy of a diabetes education programme for type 1 diabetes (PRIMAS) in a randomised controlled trial setting and the effectiveness in a routine care setting : Results of a comparative effectiveness study, in: Bamberg: opus.

Details

Faculty/Chair
Author
Bergis-Jurgan, Nikola
Haak, Thomas
Corporate Body
Research Institute of the Diabetes Academy Mergentheim
Publisher Information
opus : Bamberg
Year of publication
2017
Pages
12
Source/Other editions
Ursprünglich in: PLoS ONE 11 (2016), 1
Year of first publication
2016
Language
English
Licence
URN
Abstract

Background: The effectiveness of an intervention in clinical practice is often reduced compared to the efficacy demonstrated in a randomised controlled trial (RCT). In this comparative effectiveness study, the RCT-proven efficacy of a diabetes education programme for type 1 diabetic patients (PRIMAS) was compared to the effectiveness observed in an implementation trial (IT) under routine care conditions.

Methods: 75 patients with type 1 diabetes received PRIMAS through an RCT, whereas 179 patients were observed in an implementation trial. Baseline characteristics and treatment outcomes at the 6-month follow-up (improvement of HbA1c, hypoglycaemia problems, and diabetes-related distress) were compared.

Results: At baseline, the type 1 diabetic patients in the RCT had a significant longer diabetes duration (18.7±12.3 vs. 13.8±12.7 yrs., p = .005), lower self-efficacy scores (21.9±4.7 vs. 23.7±6.1, p = .02) and a greater number of diabetes complications (0.8±1.3 vs. 0.4±0.9, p = .02). After 6 months, PRIMAS achieved comparable effects under RCT and implementation trial conditions, as demonstrated by improvement in HbA1c (-0.36%±1.1 vs. -0.37±1.2; Δ -0.01, 95% CI -0.33 to 0.31) and hypoglycaemia unawareness (-0.5±1.4 vs. -0.3±1.4; Δ 0.18, 95% CI -0.21 to 0.57). The likelihood of clinical improvement did not depend on the trial setting (RCT vs. IT: OR 1.18, 95% CI 0.60 to 2.33). The participants with worse glycaemic control (OR 1.40, 95% CI 1.02 to 1.92), hypoglycaemia problems (OR 2.13, 95% CI 1.53 to 2.97) or elevated diabetes distress (OR 1.40, 95% CI 1.03 to 1.89) had a better chance of clinical improvement.

Conclusions: The effectiveness of PRIMAS under routine care conditions was comparable to the efficacy demonstrated in the RCT. Clinical improvement was independent of the setting in which PRIMAS was evaluated. The PRIMAS education programme for type 1 diabetes can be delivered under conditions of routine care without a loss of effectiveness, compared to its original evaluation in an RCT.

Keywords
PRIMAS
Insulin therapy
Peer Reviewed
yes
International Distribution
yes
Open Access Journal
yes
Type
Article
URI
Activation date
2017-03-30, 2017-03-30

Permalink: https://fis.uni-bamberg.de/handle/uniba/41760 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.